Metabolic syndrome and risk for Type 2 diabetes

References

• Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102, 42–47 (2000).
   PubMed Web of Science ®Google Scholar
• Meigs JB, Mittleman MA, Nathan DM et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283, 221–228 (2000).
   PubMed Web of Science ®Google Scholar
• Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors of the insulin resistance syndrome. Am. J. Epidemiol. 152(10), 897–907 (2000).
   PubMed Web of Science ®Google Scholar
• Reaven GM. Role of insulin resistance in human disease. Diabetes 37, 1595–1607 (1988).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 41, 715–722 (1992).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med. 16(5), 442–443 (1999).
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998).
   PubMed Web of Science ®Google Scholar
• Einhorn D, Reaven GM, Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237–252 (2003).
   PubMedGoogle Scholar
• Alexander CM. The coming of age of the metabolic syndrome. Diabetes Care 26, 3180–3181 (2003).
   PubMed Web of Science ®Google Scholar
• Vinicor F, Bowman B. The metabolic syndrome: the emperor needs some consistent clothes. Diabetes Care 27, 1243; author reply 1244 (2004).
   PubMed Web of Science ®Google Scholar
• Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28, 2289–2304 (2005).
   PubMed Web of Science ®Google Scholar
• Ford ES. Rarer than a blue moon: the use of a diagnostic code for the metabolic syndrome in the US. Diabetes Care 28, 1808–1809 (2005).
   PubMed Web of Science ®Google Scholar
• Boyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 24, 1936–1940 (2001).
   PubMed Web of Science ®Google Scholar
• Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA 294, 1255–1259 (2005).
   Google Scholar
• Fox CS, Coady S, Sorlie PD et al. Trends in cardiovascular complications of diabetes. JAMA 292, 2495–2499 (2004).
   PubMed Web of Science ®Google Scholar
• Shulman GI. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171–176 (2000).
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with Type 2 diabetes. N. Engl. J. Med. 350, 664–671 (2004).
   PubMed Web of Science ®Google Scholar
• Clark MG, Wallis MG, Barrett EJ et al. Blood flow and muscle metabolism: a focus on insulin action. Am. J. Physiol. Endocrinol. Metab. 284, E241–E258 (2003).
   PubMed Web of Science ®Google Scholar
• Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. The natural history of progression from normal glucose tolerance to Type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 52, 1475–1484 (2003).
   PubMed Web of Science ®Google Scholar
• Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of Type 2 diabetes. Diabetes Care 25, 1129–1134 (2002).
   PubMed Web of Science ®Google Scholar
• Despres J-P, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334, 952–957 (1996).
   PubMed Web of Science ®Google Scholar
• Rewers M, Zaccaro D, D'Agostino R et al. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27, 781–787 (2004).
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM. Cardiovascular disease risk factors predict the development of Type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 27, 2234–2240 (2004).
   PubMed Web of Science ®Google Scholar
• Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46, 459–469 (2003).
   PubMed Web of Science ®Google Scholar
• Tschritter O, Fritsche A, Thamer C et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 239–243 (2003).
   PubMed Web of Science ®Google Scholar
• Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of Type 2 diabetes mellitus. JAMA 291, 1978–1986 (2004).
   PubMed Web of Science ®Google Scholar
• Yarnell JW, Patterson CC, Bainton D, Sweetnam PM. Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies. Heart 79, 248–252 (1998).
   PubMed Web of Science ®Google Scholar
• Schmidt MI, Watson RL, Duncan BB et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism 45, 699–706 (1996).
   PubMed Web of Science ®Google Scholar
• Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders. Diabetes 47, 1643–1649 (1998).
   PubMed Web of Science ®Google Scholar
• Wilson PWF, Kannel WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med. 159, 1104–1109 (1999).
   PubMed Web of Science ®Google Scholar
• Liese AD, Mayer-Davis EJ, Tyroler HA et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann. Epidemiol. 7, 407–416 (1997).
   PubMed Web of Science ®Google Scholar
• Wei M, Gaskill SP, Haffner SM, Stern MP. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican–Americans: a 7-year prospective study. Obes. Res. 5, 16–23 (1997).
   PubMedGoogle Scholar
• Palaniappan L, Carnethon MR, Wang Y et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27, 788–793 (2004).
   PubMed Web of Science ®Google Scholar
• Carr DB, Utzschneider KM, Hull RL et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53, 2087–2094 (2004).
   PubMed Web of Science ®Google Scholar
• Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am. J. Epidemiol. 152, 908–911 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D’Agostino RB Sr, Parise H, Sullivan L, Meigs JB. The metabolic syndrome as a precursor of cardiovascular disease and Type 2 diabetes mellitus. Circulation 112, 3066–3072 (2005).
   PubMed Web of Science ®Google Scholar
• Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53, 1195–1200 (2004).
   PubMed Web of Science ®Google Scholar
• Liao Y, Kwon S, Shaughnessy S et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27, 978–983 (2004).
   PubMed Web of Science ®Google Scholar
• Bonora E, Targher G, Formentini G et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet. Med. 21, 52–58 (2004).
   PubMed Web of Science ®Google Scholar
• Bruno G, Merletti F, Biggeri A et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in Type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27, 2689–2694 (2004).
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of Type 2 diabetes: the San Antonio heart study. Diabetes Care 26, 3153–3159 (2003).
   PubMed Web of Science ®Google Scholar
• Resnick HE, Jones K, Ruotolo G et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26, 861–867 (2003).
   PubMed Web of Science ®Google Scholar
• Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the ‘metabolic syndrome’ and incidence of Type 2 diabetes. Diabetes 51, 3120–3127 (2002).
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 156, 1070–1077 (2002).
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 25, 1790–1794 (2002).
   PubMed Web of Science ®Google Scholar
• Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108, 414–419 (2003).
   PubMed Web of Science ®Google Scholar
• Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28, 1769–1778 (2005).
   PubMed Web of Science ®Google Scholar
• Edelstein SL, Knowler WC, Bain RP et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46, 701–710 (1997).
   PubMed Web of Science ®Google Scholar
• Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am. J. Epidemiol. 159, 882–890 (2004).
   PubMed Web of Science ®Google Scholar
• Schmidt MI, Duncan BB, Bang H et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 28, 2013–2018 (2005).
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of Type 2 diabetes and/or cardiovascular disease? Diabetes Care 27, 2676–2681 (2004).
   PubMed Web of Science ®Google Scholar
• Stern MP, Williams K, Haffner SM. Identification of persons at high risk for Type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann. Intern. Med. 136, 575–581 (2002).
   PubMed Web of Science ®Google Scholar
• Bonora E, Kiechl S, Willeit J et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int. J. Obes. Relat. Metab. Disord. 27, 1283–1289 (2003).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107, 391–397 (2003).
   PubMed Web of Science ®Google Scholar
• Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110, 380–385 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson PWF, Meigs JB, Sullivan L, Nathan DM, D’Agostino Sr RB. Prediction rule for incident Type 2 diabetes in Framingham offspring. Diabetes 54(Suppl. 1), A91 (2005).
   Google Scholar
• Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 46(Suppl. 2), S9–S13 (1997).
   PubMed Web of Science ®Google Scholar
• Caballero AE, Arora S, Saouaf R et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for Type 2 diabetes. Diabetes 48, 1856–1862 (1999).
   PubMed Web of Science ®Google Scholar
• Meigs JB, Wilson PWF, Tofler GH et al. Markers of endothelial dysfunction predict incident Type 2 diabetes. Diabetes 54(Suppl. 1), A90 (2005).
   Google Scholar
• Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against Type 2 diabetes mellitus. Lancet 361, 226–228 (2003).
   PubMed Web of Science ®Google Scholar
• Lindsay RS, Funahashi T, Hanson RL et al. Adiponectin and development of Type 2 diabetes in the Pima Indian population. Lancet 360, 57–58 (2002).
   PubMed Web of Science ®Google Scholar
• LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation 112, 505–512 (2005).
   PubMed Web of Science ®Google Scholar
• Esposito K, Marfella R, Ciotola M et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292, 1440–1446 (2004).
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142, 611–619 (2005).
   PubMed Web of Science ®Google Scholar
• Ilanne-Parikka P, Eriksson JG, Lindstrom J et al. Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care 27, 2135–2140 (2004).
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Eringa E, Stehouwer CD. ‘Vasocrine’ signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365, 1817–1820 (2005).
   PubMed Web of Science ®Google Scholar
• Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 87, 563–568 (2002).
   PubMed Web of Science ®Google Scholar
• O’Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 33, 1506–1511 (1999).
   PubMed Web of Science ®Google Scholar
• Golay A, Despres JP, Sjostrom L. Rimonabant improves glycemic control parameters and glucose tolerance in overweight/obese nondiabetic subjects with dyslipidemia. RIO-lipids trial. Diabetologia 47(Suppl. 1), A71 (2004).
   Google Scholar